huNOG-EXL SA (Standard Access)

Humanized Immune System Mouse Model

huNOG-EXL SA (Standard Access) Mouse model
Order This Model OR Request a Quote
CALL: 888.822.6642 + 45 70 23 04 05 (EUROPE and DENMARK) +49 214 50 68 023 (GERMANY)
Now available from US and EU production sites.

NOD Background

  • Model #
  • Genotype
  • Nomenclature
  • HSCCB-13395-F
    sp/sp;ko/ko;tg/wt
    NOD.Cg-Prkdcscid Il2rgtm1Sug Tg(SV40/HTLV-IL3,CSF2)10-7Jic/JicTac

A Humanized Immune System (HIS) Mouse Supporting Both Myeloid & Lymphoid Cells

For researchers who want access to live inventory for immediate delivery, the huNOG-EXL SA (Standard Access) is the ideal model, particularly for experiments with shorter timelines or studies that must start as soon as possible.

Taconic's portfolio of HIS mice includes both the huNOG-EXL SA (Standard Access) as well as the huNOG-EXL EA (Early Access). Both SA and EA models are available with simple terms of use and are individually applicable for different research goals.

Compare the huNOG-EXL SA and EA models to learn which is right for your project.

  • Humanized immune system mouse generated through engraftment of human CD34+ hematopoietic stem cells (HSCs) in NOG-EXL mice, available as an inventoried, study-ready product.
  • All mice shipped meet a specified QC standard of ≥25% hCD45 in peripheral blood at 10 weeks post-engraftment.
  • NOG-EXL host strain is a super immunodeficient NOG mouse expressing human GM-CSF and human IL-3 cytokines to support myeloid lineage engraftment.
  • Higher overall engraftment levels of human hematopoietic stem cells (HSC) compared to core NOG mouse. In most cases, huNOG-EXL mice average>40% human cells in blood.
  • Higher levels of myeloid cell differentiation following human HSC engraftment compared to core NOG mouse.
  • Applications in research involving oncology and immuno-oncology, autoimmune disease, allergy, infectious disease, immunology, regenerative medicine, safety assessment, and humanization.
  • Humanized immune system mice require special housing and husbandry. We recommend reviewing the the comprehensive document Licensing, Care & Resources for Taconic's Humanized Immune System Models and the Video: Care of HIS mice for experimental success prior to ordering. We strongly recommend that customers schedule a complimentary consultation with a Field Application Scientist prior to ordering so as to maximize experimental success.
Not sure which huNOG-EXL product to choose? See below to view our in-depth comparison chart. Taconic's PhD Field Applications Scientists can also help you determine which model is best suited for your study.

Which huNOG-EXL is right for you?

 huNOG-EXL SAhuNOG-EXL EA
Price+++
TimelineInventoried at 10+ WPE and ready to go on study after a short acclimation5-6 week order lead time; shipped 1-2 WPE
Available for experimental manipulation prior to 10 WPENoYes
Chimerism QC data availableYesNo
Who assumes the risk that individual animals fail to engraft?TaconicCustomer
% mice guaranteed to meet QC standard100%N/A
Maximum n-value per donor?35-40 mice35-40 mice
Minimum purchaseNo minimum20 mice
Cancellation policyCancellation deadline 4 weeks prior to ship dateMay not be canceled after order is booked
Orders by weight: Taconic cannot accept orders by weight for this model. Please note that shipments may contain animals with a larger weight variation.

Related Taconic InsightRead the Related Taconic Biosciences' Insight:

Origin:

hGM-CSF/hIL3 NOG mice engrafted with human CD34+ hematopoietic stem cells (HSCs) stably develop extensive cell lineages as early as 6 to 8 weeks post-injection. Both myeloid and lymphoid lineage cells are present in peripheral blood, bone marrow, thymus and spleen and non-lymphoid tissue including lung and liver. While not all human immune cell types have been exhaustively characterized in these mice, extensive myeloid differentiation including granulocyte lineages (basophil, neutrophil and mast cells) are evident in blood and tissues. Antigen presenting cells (dendritic cells and macrophages) are also increased in frequency, both in blood and spleen.

Availability:

  • Taconic maintains an inventory of female huNOG-EXL mice engrafted as juveniles and FACS tested at 10 weeks post-engraftment.
  • Custom options such as HLA selection for huNOG-EXL Standard Access are available with additional fee. Inquire regarding your specific needs.
  • Orders with a specification regarding number of mice per donor are subject to availability and are not guaranteed, as orders may need to be adjusted at time of packing.
NOTE: Please contact Taconic prior to your first order for a review of unpacking instructions. Tattoo numbers may repeat between engraftment lots. Individual ID number is determined through examination of the tattoo PLUS the box and section location.

Lifespan: All myeloid-supportive HIS mice have limited lifespans due to a range of outcomes including anemia, thrombocytopenia, macrophage activation syndrome and hemophagocytic lymphohistiocytosis. The huNOG-EXL has the longest demonstrated lifespan compared to competing models, but this varies by donor and can be impacted by environmental and experimental factors. While Taconic has observed that huNOG-EXL mice can often survive for 30+ weeks post-engraftment (WPE), researchers should plan for a typical study window of 26-30 WPE.

Color:

Albino

Species:

Mouse

Initial Publication:

  • Ito M, Hiramatsu H, Kobayashi K, Suzue K, Kawahata M, Hioki K, Ueyama Y, Koyanagi Y, Sugamura K, Tsuji K, Heike T, Nakahata T. (2002) NOD/SCID/γnull/c mouse: an excellent recipient mouse model for engraftment of human cells. Blood 100(9):3175-3182.
  • Fukuchi Y, Miyakawa Y, Kobayashi K, Kuramochi T, Shimamura K, Tamaoki N, Nomura T, Ueyama Y, Ito M. (1998) Cytokine dependent growth of human TF-1 leukemic cell line in human GM-CSF and IL-3 producing transgenic SCID mice. Leuk Res 22(9):837-43.
  • Ito R, Takahashi T, Katano I, Kawai K, Kamisako T, Ogura T, Ida-Tanaka M, Suemizu H, Nunomura S, Ra C, Mori A, Aiso S, Ito M. (2013) Establishment of a human allergy model using human IL-3/GM-CSF-transgenic NOG mice. J Immunol.191(6):2890-9.


Nonprofit users (excluding users at nonprofit foundations which are affiliated with a for-profit entity): For internal research purposes, the CIEA NOG mouse® Conditions of Use for nonprofit users apply. If you wish to perform sponsored research or fee-for-service contract research using the CIEA NOG mouse®, please inquire for access conditions

For-profit users and users at foundations which are affiliated with for-profit entities: The CIEA NOG mouse® Conditions of Use for for-profit users apply.

The CIEA NOG mouse® is produced and distributed under license rights to the following patents and trademarks:
  • Japanese Patent No. 3,753,321
  • US Patent No. 7,145,055; 5,464,764; 5,487,992; 5,627,059; 5,631,153; 5,789,215; 6,204,061; 6,653,113; 6,689,610
    EP Patent No. 1,338,198
  • Japanese Trademark Reg. No. 4,823,423
  • US Trademark Reg. No. 3,118,040
  • EU Trademark Reg. No. 3,736,758
Conditions of Use specific to models generated using CRISPR/Cas9
This Model was generated using CRISPR/Cas9 technology. Taconic uses CRISPR/Cas9 technology to generate and/or distribute gene-edited models under licenses from The Broad Institute, Inc., the Massachusetts Institute of Technology, the President and Fellows of Harvard College, the University of Iowa Research Foundation and ERS Genomics. View the full list of licensed patents:
  • This Model and biological materials derived from it may only be used for purchasers' internal research purposes in the Field, unless purchaser otherwise has rights from the Broad covering such use. "Field" means use as a research tool for research purposes, and expressly excludes any (a) clinical use, (b) human, veterinary, livestock or agricultural use, or (c) manufacture, distribution, sale, promotion, use or other exploitation as a testing service, therapeutic or diagnostic for humans or animals.
  • The Models and biological materials derived from them will not be sold or used to perform services for third parties (unless purchaser is acting on behalf of a third party to which they have communicated these Conditions of Use and which third party has accepted these Conditions of Use), or otherwise used for commercial purposes.
  • Purchasers will only use the Models and biological materials derived from them in compliance with all applicable laws and regulations, including applicable human health and animal welfare laws and regulations.
  • Each non-profit purchaser agrees that it, and not Taconic's licensors, shall be responsible for any liability, damage, loss or expense arising out of or related to purchaser's use of the purchased Models and any biological materials derived from them , including any breach of the Label License "Conditions of Use for Taconic Transgenic Models" by purchaser.
  • Each for-profit purchaser further agrees that it shall indemnify, defend and hold harmless Taconic's licensors against any liability, damage, loss, or expense (including without limitation reasonable attorneys' fees and expenses) incurred by or imposed upon any of Taconic's licensors in connection with any claims, suits, investigations, actions, demands or judgments arising out of or related to purchaser's use of the purchased Models and any biological materials derived from them.
  • Each purchaser acknowledges that the purchased Models and any biological materials derived from them and its use may be the subject of one or more issued patents and/or pending patent applications owned by Taconic's licensors, and the purchase of the Models does not convey a license under any claims in the foregoing patents or patent applications.

Kinetics of human immune cell reconstitution in huNOG-EXL (peripheral blood)
Figure 1: Kinetics of human immune cell reconstitution in huNOG-EXL (peripheral blood). huNOG-EXL mice support high levels of human immune cells in peripheral blood (chimerism) and develop both myeloid and lymphoid cells. huNOG-EXL EA mice are shipped shortly after engraftment, prior to reconstitution of significant numbers of human immune cells in peripheral blood. huNOG-EXL SA mice are shipped after a QC step to confirm that each mouse has ≥25% human cells in peripheral blood at 10 weeks post-engraftment.

How Taconic Addresses HIS Mouse Variability

How Taconic Addresses HIS Mouse Variability
Figure 2: Donor characteristics impact human immune system reconstitution in huNOG-EXL mice, including chimerism levels and frequencies of specific human immune cell types. For huNOG-EXL SA, lots for which the mean falls below Taconic's 25% chimerism threshold are disqualified from sale (lots shown in red). For lots with a mean above the threshold (shown in blue), any individual animals in the lot which score below 25% are disqualified from sale. For huNOG-EXL EA, Taconic selects donors that have previously been validated to reduce the risk of lot failure. Taconic's Field Application Scientists can help you design a successful study plan which appropriately accounts for both inter- and intra-donor variation in HIS mice.

huNOG-EXL EA Mice are Engrafted Using Donor Cells with Proven Engraftment Success

huNOG-EXL EA mice are engrafted using donor cells with proven engraftment success
Figure 3: HSCs from the same donor were engrafted twice, on separate days (A and B), to generate two lots of huNOG-EXL mice per donor. The ability of a donor to produce lots where most mice met or failed the QC threshold of ≥25% chimerism was replicated between duplicate lots, with one exception in this test set. To make huNOG-EXL EA mice, Taconic chooses donors with proven engraftment success in order to reduce the risk of lot failure.

Enhanced Myeloid Engraftment in Humanized NOG-EXL Mice

Stable engraftment with significant improvement in myeloid lineage reconstitution and overall cellularity

Stable engraftment with significant improvement in myeloid lineage reconstitution and overall cellularity
Figure 4: (a) High humanization rate is observed across multiple donors in huNOG-EXL. NOG-EXL (hGM-CSF/hIL-3 NOG) mice were engrafted with human CD34+ hematopoietic stem cells (HSCs) from n=11 different donors and peripheral blood humanizations was monitored by hCD45 antibody. (b) huNOG-EXL mouse supports development of both myeloid and lymphoid cells.

Better engraftment of myeloid populations in huNOG-EXL mice

Better engraftment of myeloid populations in huNOG-EXL mice
Figure 5: Frequencies of CD14+ CD16- (classical) monocytes from FSC-Ahi CD3- cells (a), HLA-DR+ Lin 1- cells from CD45+ cells (b), CD11c- CD123+ plasmacytoid dendritic cells (c), and CD11c+ CD123- myeloid dendritic cells (d), the latter from HLA-DR+ Lin 1- cells, in blood (diamonds) and secondary lymphoid organs (SLO; spleen: circles; axillary lymph node: squares; mesenteric lymph node: triangles) from huNOG-EXL and huNSG mice. NS: Not statistically significant. Adapted from Perdomo-celis, et al. 2019 under Creative Commons Attribution License.

Human immune cell subsets in huNOG-EXL mice

Human immune cell subsets in huNOG-EXL mice
Figure 6: Representative gating strategy from blood cells for the identification of the cell populations evaluated. The number next to the gates represents the respective cell subset found in the adjacent table. Adapted from Perdomo-celis, et al. 2019 under Creative Commons Attribution License.

Tumor Xenograft Models and Immunotherapy Research with huNOG-EXL

Durable anti-tumor response to combination therapy in huNOG-EXL BRCA-deficient tumor model

Durable anti-tumor response to combination therapy in huNOG-EXL BRCA-deficient tumor model
Figure 7: (a) Tumor growth curve for the MDA-MB-436 NOG-EXL humanized model treated with control or 35 mg/kg niraparib daily for 5 days on and 2 days off for 4 weeks (QD × 5 × 4). (b) Significantly upregulated genes identified with a two-sample t test (p <=0.05, fold change>=1.5) were subjected to enrichment analysis of pathway gene sets and demonstrated a significant enrichment of interferon gamma signature and interferon alpha signature genes in niraparib-treated samples. (c-e) Niraparib promoted tumor immune cell infiltration in BRCA-deficient MDA-MB-436 huNOG-EXL humanized tumor model. (f) Tumor growth in the BRCA-deficient MDA-MB-436 model in huNOG-EXL mice treated with 200 mg anti-PD-1 (pembrolizumab) on days 0, 4, 9, 13, 18, 22, and 28; 35 mg/kg niraparib daily for 5 days on and 2 days off for 4 weeks; and the combination of these agents. Adapted from Wang, et al. 2019 under Creative Commons Attribution License.

Immunophenotyping and anti-CTLA4 human immune response in huNOG-EXL mice

Immunophenotyping and anti-CTLA4 human immune response in huNOG-EXL mice
Figure 8: (a) Anti-CTLA4 antibody pharmacokinetics in huNOG-EXL mice. (b) Splenic immunophenotyping of huNOG-EXL mice treated with anti-CLTA4 antibodies. NF: nonfucosylated. Data provided by Dr. Kathryn Fraser, Takeda.

Infectious Disease Research with huNOG-EXL

HIV infection in huNOG-EXL mice affects the frequencies of human immune cells

HIV infection in huNOG-EXL mice affects the frequencies of human immune cells
Figure 9: Frequencies of CD3+ cells (a), CD20+ cells (b), CXCR5+ CD4+ T-cells (c), CXCR5+ CD8+ T-cells (d), CD14+ CD16- (classical) monocytes from FSC-Ahi CD3- cells (e), HLA-DR+ Lin 1- cells from CD45+ cells (f), CD11c- CD123+ plasmacytoid dendritic cells from HLA-DR+ Lin 1- cells (g), CD56dim (h), and CD56bright NK cells (i) in huNOG-EXL mice after infection with HIV. Adapted from Perdomo-celis, et al. 2019 under Creative Commons Attribution License.
Close

Welcome! Tell us a little about yourself